Business Highlights Q4 2013
Financial Highlights FY 2013 (FY 2012)
"Sobi had an eventful year in 2013 with strong operating performance and significant pipeline progress. Revenues in the fourth quarter rose by 29 per cent and by 13 per cent in the year, and we expanded our business in both new and existing markets. Our gross margin increased substantially and we strengthened our company financially through positive cash flow and improved operating profit," said Geoffrey McDonough, CEO and President. "We also presented new data from our adult and paediatric haemophilia programmes with Biogen Idec, completed enrolment for our pivotal Kiobrina® phase 3 trial, and announced new initiatives for Kepivance® in Head and Neck Cancer and for SOBI002, our novel biologic inhibitor of complement factor C5."
For 2014, Sobi expects total revenues for the full year to be in the range of SEK 2,300 to 2,500 M and the gross margin to be in the range of 58-60 per cent. Operating costs are expected to increase as the company continues to prepare for the planned launch of the three phase 3 pipeline programmes.